Plasma Fibrin Clot Properties Are Unfavorably Altered in Women following Venous Thromboembolism Associated with Combined Hormonal Contraception

Abstract EN

The use of hormonal contraception is associated with an increased risk of venous thromboembolism (VTE).

Unfavorably altered fibrin clot phenotype has been reported in patients following unprovoked VTE who are at risk of recurrences.

It remains unknown whether fibrin clot characteristics in women with contraception-related VTE differ from those in unprovoked VTE.

We studied three age-matched groups of women: (1) after contraception-related VTE, (n=48) (2) after unprovoked VTE (n=48), and (3) controls (n=48).

Plasma fibrin clot permeability (Ks), turbidity of clot formation, efficiency of fibrinolysis using clot lysis time (CLT), and rate of increase in D-dimer during lytic clot degradation (D-Drate), along with thrombin generation and fibrinolysis proteins were determined.

Compared with the controls, patients following contraception-related and unprovoked VTE formed faster (lag phase, -8.8% and -20.4%, respectively) fibrin clots of increased density (Ks, -8.6% and -13.4%, respectively) displaying impaired fibrinolysis as evidenced by prolonged CLT (+11.5% and +14.5%, respectively) and lower D-Drate (-7.1% and -5.6%, respectively), accompanied with higher plasminogen activator inhibitor-1 (PAI-1, +14.9% and +17.8%, respectively) and elevated peak thrombin generation (+63.8% and +36.7%, respectively).

The only differences between women with unprovoked and contraception-related VTE were lower fibrin mass in plasma clots (D-Dmax, -8.6%), along with higher peak thrombin generation (+19.8%) and shorter lag phase (-6.8%) in the latter group.

This study suggests that women after contraception-related VTE, similar to those following unprovoked VTE, have denser fibrin clot formation and impaired clot lysis.

These findings might imply higher risk of VTE recurrence in women with the prothrombotic clot phenotype.